Fundamental Analysis of PREDICTIVE ONCOLOGY INC(NASDAQ:POAI) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to POAI. POAI was compared to 195 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of POAI have multiple concerns. POAI has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.

In the past year POAI has reported a negative cash flow from operations.

POAI had negative earnings in each of the past 5 years.

In the past 5 years POAI always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -96.93%, POAI is not doing good in the industry: 82.05% of the companies in the same industry are doing better.

POAI has a Return On Equity of -168.95%. This is in the lower half of the industry: POAI underperforms 77.95% of its industry peers.

		Industry Rank	Sector Rank
ROA	-96.93%
ROE	-168.95%
ROIC	N/A

ROA(3y)-80.65%

ROA(5y)-106.47%

ROE(3y)-112.04%

ROE(5y)-302.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

POAI has a better Gross Margin (64.26%) than 65.13% of its industry peers.

In the last couple of years the Gross Margin of POAI has declined.

The Profit Margin and Operating Margin are not available for POAI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	64.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.24%

GM growth 5Y-1.93%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, POAI has more shares outstanding

POAI has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, POAI has a worse debt to assets ratio.

2.2 Solvency

POAI has an Altman-Z score of -18.33. This is a bad value and indicates that POAI is not financially healthy and even has some risk of bankruptcy.

POAI's Altman-Z score of -18.33 is on the low side compared to the rest of the industry. POAI is outperformed by 86.15% of its industry peers.

POAI has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

POAI has a better Debt to Equity ratio (0.02) than 64.62% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	-18.33

ROIC/WACCN/A

WACC10.14%

2.3 Liquidity

POAI has a Current Ratio of 2.55. This indicates that POAI is financially healthy and has no problem in meeting its short term obligations.

POAI has a worse Current ratio (2.55) than 60.00% of its industry peers.

A Quick Ratio of 2.43 indicates that POAI has no problem at all paying its short term obligations.

With a Quick ratio value of 2.43, POAI perfoms like the industry average, outperforming 50.77% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.55
Quick Ratio	2.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.98% over the past year.

POAI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.00%.

Measured over the past years, POAI shows a small growth in Revenue. The Revenue has been growing by 4.77% on average per year.

EPS 1Y (TTM)50.98%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q57.44%

Revenue 1Y (TTM)19%

Revenue growth 3Y12.51%

Revenue growth 5Y4.77%

Revenue growth Q2Q-6.94%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for POAI. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for POAI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (4/24/2024, 3:00:00 PM)

1.34

+0.05 (+3.88%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap5.44M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-96.93%
ROE	-168.95%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	64.26%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.12

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.55
Quick Ratio	2.43
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)50.98%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)19%

Revenue growth 3Y12.51%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PREDICTIVE ONCOLOGY INC (POAI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens